For decades, p53 – the ‘guardian of the genome’ – has been oncology’s great white shark: a critical tumour suppressor implicated in over 50% of cancers, yet stubbornly resistant to therapeutic intervention.

In a dramatic scientific plot twist, multiple companies are now racing to crack the code of the common Y220C mutation, with several novel approaches coming through. These range from non-covalent and covalent protein reactivators or stabilisers to heterobifunctional glues and even mRNA approaches.

The scientific breakthrough eluding researchers for generations may finally be within reach, potentially changing outcomes for many cancer patients who harbour this specific genetic alteration.

In a candid interview with one the companies actively involved in research in this niche, we learned more about what’s in store and what to watch out for…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by